Strengthened70% impact weight
The contested handling and suspension of the Dengvaxia program is widely cited as a major boost to vaccine hesitancy and distrust of immunization in the Philippines. Causal magnitude is debated, hence medium confidence.
actionneeds reviewconfidence: high
Philippines suspends Dengvaxia dengue-vaccination program after Sanofi safety warning (2017)
After the Department of Health launched a school-based dengue vaccination campaign with Sanofi Pasteur's Dengvaxia in April 2016 (reaching roughly 700,000+ children), Sanofi warned on 29 November 2017 that the vaccine could raise the risk of severe dengue in people not previously infected. The DOH suspended the program in late November 2017 and later banned the vaccine. The episode is widely cited as a major driver of subsequent vaccine hesitancy in the Philippines.
- Contributor1
- This fact
- Driver1
- Indicators2
What happened
After the Department of Health launched a school-based dengue vaccination campaign with Sanofi Pasteur's Dengvaxia in April 2016 (reaching roughly 700,000+ children), Sanofi warned on 29 November 2017 that the vaccine could raise the risk of severe dengue in people not previously infected. The DOH suspended the program in late November 2017 and later banned the vaccine. The episode is widely cited as a major driver of subsequent vaccine hesitancy in the Philippines.
Causal network
This fact’s slice of Factrail’s verified causal web — the people, facts, drivers and welfare indicators it connects to. Select any node to trace a path.
Loading network…